Been waiting for weeks, or at least a quarter for the Pharmaceutical stocks to turn bullish.
And with the Nasdaq Biotechnology Index breaking out of the consolidation phase at 3158, and Donald Trump finally making good his healthcare reforms, the suppressed undervalued pharmaceutical stocks should start to shine moving forward.
As such Household pharmaceutical names like Glaxosmithkline (GSK) or Pfizer (PFE) are worth putting on one's watch list.